BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals reported Q2 2026 results driven by ORLADEYO capsule demand, with total revenue up 45% YoY excluding divested European operations. Management said it ended internal drug discovery and closed its Birmingham unit. Full-year 2026 ORLADEYO guidance remains $625M to $645M. Cash and investments were over $350M.

BIOCRYST PHARMACEUTICALS INC (BCRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 BioCryst Reports Second Quarter 2026 Financial Results — Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 mil

Biotech news roundup: Novartis (NVS) won EU approval for Itvisma for SMA; HUTCHMED (HCM) got China approval for ORPATHYS (savolitinib) in MET-amplified gastric cancer; Vertex (VRTX) expanded CASGEVY to children as young as 2; Unicycive (UNCY) received an FDA CRL for its CKD dialysis NDA; Ipsen (IPN.PA) agreed to buy Memo Therapeutics (~€700m) and Kartos ($450m).

BioCryst said it expects ORLADEYO to reach $1B peak sales, citing payer mix of ~60% commercial, 20% Medicare Part D and 20% Medicaid and gross-to-net around 15% last year. Pediatric ORLADEYO launch was delayed by a batch manufacturing issue, not safety-related. In Phase 3, navenibart ALPHA-ORBIT enrollment should finish by end-June; top-line data due Q3 next year, with a likely 2H 2028 launch. BioCryst reported pro forma cash of $330M and expects profitability this year and next.

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.

U.S. health authorities are investigating a Salmonella outbreak linked to Mexican jalapeño peppers. The CDC and FDA say 345 people are ill across 27 states, with 36 hospitalizations and no deaths. The supplier, Coast Citrus Distributors, recalled peppers sent to restaurants including Chipotle and QDOBA. Chipotle removed jalapeños from some outlets and shares fell over 8% on Aug. 4.